OMEICOS
develops and commercializes small molecule therapeutics for the treatment of cardiovascular, fatty liver and bronchial diseases... Read moreOMEICOS
develops and commercializes small molecule therapeutics for the treatment of cardiovascular, fatty liver and bronchial diseases... Read more
News
Jan 29, 2026
StreetInsider
Press Release: OMEICOS : OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28's Potential in Primary Mitochondrial Diseases (PMD)
Sep 26, 2024
StreetInsider
Press Release: OMEICOS : OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
Apr 29, 2019
BioPortfolio
OMEICOS: OMEICOS Therapeutics Announces FirstDosing in Phase 2 Clinical Study Evaluating its Lead Program OMT28 in Patients with Persistent Atrial Fibrillation
Apr 29, 2019
Drug Development Technology
OMEICOS: Omeicos doses first patient in Phase II trial of OMT-28 programme
Feb 11, 2019
Talent4Boards
OMEICOS: OMEICOS Therapeutics appoints Dr Christian Schetter to its Supervisory Board as Independent Director
Nov 02, 2018
EU-Startups
OMEICOS: Berlin-based OMEICOS Therapeutics has raised €17 million to develop treatments for heart arrhythmia
Sep 27, 2018
BioPortfolio
OMEICOS: OMEICOS Therapeutics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250
Aug 07, 2018
BioPortfolio
OMEICOS: OMEICOS Therapeutics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 10052018 Prices from USD $250
Jul 17, 2018
FinanzNachrichten
OMEICOS: OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation
Apr 27, 2018
StreetInsider
Press Release: OMEICOS : Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics
OMEICOS Competitors
1
2
3
4
5
6
7
8
9
10